Immix Biopharma · pitchdeck
Immix Biopharma | Investor Presentation Deck | 60 slides
60 pages · 5 arc beats · 2 loops
Immix Biopharma | Investor Presentation Deck | 60 slides
Immix Biopharma · 2023-11 arc beats above · slides in the middle · loops below · scroll → 2 LOOPS
124681012141618202224262830323436384042444648505254565860
Deck intelligence map
5 coverage by narrative range · generated from this deck JSON
Narrative range 33 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 5 hits — 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides 100% 1/1 slides · 2 hits Solution 2 slides 100% 2/2 slides 100% 2/2 slides · 15 hits — 0/2 slides
100% 2/2 slides 50% 1/2 slides 100% 2/2 slides 100% 2/2 slides Market Sizing 1 slides 100% 1/1 slides 100% 1/1 slides · 6 hits — 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides · 2 hits 100% 1/1 slides Competitive Analysis 12 slides 100% 12/12 slides 100% 12/12 slides · 57 hits — 0/12 slides
16.7% 2/12 slides 58.3% 7/12 slides 100% 12/12 slides · 17 hits 100% 12/12 slides · 16 hits Traction 17 slides 100% 17/17 slides 100% 17/17 slides · 82 hits — 0/17 slides
5.9% 1/17 slides 64.7% 11/17 slides 100% 17/17 slides · 23 hits 100% 17/17 slides Slide inventory
60 every slide · same image gating as the playbook
03
The slide uses a numbered list format to present key value propositions.summarize
Open slide detailLoop · Golden Circle
04
The slide uses a grid-based layout to categorize team members into three distinct groups: Leadership, Board of Directors, and Scientific Advisory Board.other
Open slide detailLoop · Golden Circle
05
The slide uses a causal-chain framework to link platform capabilities to strategic outcomes.present_solution
06
Includes a biological process diagram showing B-cell development and target markers (CD19, CD20, BCMA).present_solution
07
Uses a hub-and-spoke diagram to illustrate the central problem of neurotoxicity and its four primary negative consequences.frame_problem
08
The slide uses a structural diagram to highlight the substitution of the 'Tumor Binding Domain' with the 'COBRA Binder' in the NXC-201 molecule.present_solution
Open slide detailLoop · Cost Of Inaction
09
The slide uses a diagram to map specific protein domains to their functional benefits.present_solution
Open slide detailLoop · Cost Of Inaction
10
The slide uses authority-citation to validate the mechanism of ITAM modification and degradation.present_solution
Open slide detailLoop · Cost Of Inaction
11
The slide uses a combination of bar charts for preclinical cytokine release and a table for clinical outcomes to demonstrate the competitive advantage of NXC-20compare_peers
12
Includes a scientific quote justifying the use of Glycine/Serine linkers.present_solution
13
Includes a cartoon liver character at the bottom.present_solution
14
The slide explicitly notes that this is a cross-trial comparison and not a head-to-head study.compare_peers
15
The slide uses a biological structural diagram to illustrate the proprietary nature of the COBRA binding domain compared to standard CAR-T constructs.present_solution
16
Includes comparative bar charts for transduction efficiency and toxicity markers, and flow cytometry data for anti-exhaustion.present_solution
17
The slide uses a multi-panel line chart with timeline bars to contrast clinical outcomes.compare_peers
18
The chart demonstrates a clear inverse relationship where the spike in HBI0101 cells corresponds to a rapid decline in dFLC levels, stabilizing around the 30-dashow_traction
19
The slide uses a causal chain framework to link cellular pathology to systemic organ damage.frame_problem
20
Includes a disclaimer about cross-trial comparison limitations.compare_peers
21
The slide uses a table structure to contrast patient segments and includes a bar chart representation for patient growth.compare_peers
22
The slide explicitly notes that these are cross-trial comparisons and not head-to-head results.compare_peers
23
Includes FDA approval precedents as a footnote to justify the clinical strategy.plan_implementation
24
Uses a visual icon-grid to represent market expansion.size_opportunity
25
Includes detailed clinical trial citations in the footer.show_traction
26
The slide uses a two-column layout to separate milestones by drug candidate.plan_implementation
27
The slide uses a standard pharmaceutical pipeline table format, categorizing assets by clinical vs. preclinical status and highlighting specific clinical trial show_traction
28
Includes a comparison table of clinical outcomes (ORR/CR/sCR) between NXC-201 and competitors.argue_timing
29
The slide uses a visual wave/area chart metaphor to represent market segments and their respective valuations.size_opportunity
30
The slide uses a red dashed box to highlight the primary efficacy metrics for comparison.compare_peers
31
The slide uses a complex table structure to compare patient demographics and clinical outcomes across three cohorts.compare_peers
32
The chart uses a grouped bar structure to compare NXC-201 (green) against other therapies (blue/red) categorized by prior BCMA treatment status.compare_peers
33
The slide uses a side-by-side comparison of two disease indications, each with its own clinical data points and relevant market benchmarks.show_traction
34
The chart demonstrates deepening clinical responses over time for NXC-201 therapy.show_traction
35
Includes a complex biological pathway diagram and three supporting charts demonstrating efficacy.present_solution
Open slide detailLoop · Golden Circle
36
The slide uses a numbered list format to present key value propositions.summarize
Open slide detailLoop · Golden Circle
38
The slide uses a step-wise diagram to illustrate dose escalation in a clinical trial setting.plan_implementation
Open slide detailLoop · Golden Circle
39
The table compares CRS and ICANS incidence and management across three dosage groups (150x10^6, 450x10^6, and 800x10^6 cells).analyze_data
Open slide detailLoop · Golden Circle
40
The slide highlights specific toxicity data (CRS and ICANS) for a competitor product.compare_peers
Open slide detailLoop · Golden Circle
41
Highlights NXC-201's lower fludarabine dose and Carvykti's longer infusion window.compare_peers
Open slide detailLoop · Golden Circle
42
The table compares four different therapies across four criteria categories: Prior lines of therapy, Toxicity recovery, ECOG, and Measurable disease.compare_peers
Open slide detailLoop · Golden Circle
43
The slide highlights a competitive advantage for NXC-201 regarding patient eligibility.compare_peers
Open slide detailLoop · Golden Circle
44
The slide uses a bar chart to compare two groups of drugs and their associated companies.size_opportunity
Open slide detailLoop · Golden Circle
45
Slide presents three distinct preclinical data sets: survival in STS mice, tumor response in STS mice, and survival in KPC pancreatic cancer mice.show_traction
Open slide detailLoop · Golden Circle
46
Includes a process flow diagram illustrating the mechanism of action of IMX-110 in tumor microenvironments.illustrate_case
Open slide detailLoop · Golden Circle
47
Includes Kaplan-Meier survival curves and bioluminescence imaging of tumor activity.show_traction
Open slide detailLoop · Golden Circle
48
Includes waterfall and spider/line plots for patient response data.show_traction
Open slide detailLoop · Golden Circle
49
The slide uses a bubble chart to map clinical trials and a table to detail drug performance metrics.size_opportunity
Open slide detailLoop · Golden Circle
50
The slide uses a combination of a conceptual chart and a data table to demonstrate efficacy in heavily pre-treated patients.show_traction
Open slide detailLoop · Golden Circle
51
The slide uses a process flow diagram to illustrate the clinical development path for two different treatment regimens.plan_implementation
Open slide detailLoop · Golden Circle
52
Includes a comparative diagram of the drug molecule vs standard IgG antibody and multiple clinical/preclinical data charts.present_solution
Open slide detailLoop · Golden Circle
53
Includes two sets of charts: tumor volume line graphs and survival curves for MDA-MB-231 and HCT-116 models.show_traction
Open slide detailLoop · Golden Circle
54
Includes detailed scientific diagrams of the drug mechanism and clinical trial results.present_solution
Open slide detailLoop · Golden Circle
55
The slide uses a bar chart comparison to highlight the efficacy gap between established treatments and placebo.compare_peers
Open slide detailLoop · Golden Circle
56
The slide uses a side-by-side comparison of two proprietary technology platforms.present_solution
Open slide detailLoop · Golden Circle
57
The slide uses a process-flow style layout to connect platform capabilities to specific product outcomes.present_solution
Open slide detailLoop · Golden Circle
58
The slide uses a serpentine process flow (1-5 left-to-right, 6-10 right-to-left).plan_implementation
Open slide detailLoop · Golden Circle
59
The slide uses a process-like flow from the 3 pillars to the specific product outcomes.present_solution
Open slide detailLoop · Golden Circle